KenOliveLab @KenOliveLab

Asc Prof. of Medicine, Columbia University, views own. Pancreatic cancer, translational therapeutics, metabolism, systems, paracrine interactions. It all fits. cancer.columbia.edu/profile/kennet… New York, NY, USA Joined August 2018

Tweets

3K
Followers

4K
Following

369
Likes

2K

KenOliveLab @KenOliveLab

2 years ago

@NCICancerBio @ednacukierman @DelgiornoKathy @CJHPhD @AshleyKiemen @Aiims1742 @CancerHacker @MaraShermanLab @NinaSteele17 Thanks for the invitation to participate! To all those who are reading, most of my social media activity going forward is on the site with the butterfly (same handle). Hope to see you over there!

1 0 2 158 0

View Details

KenOliveLab @KenOliveLab

2 years ago

@NCICancerBio A9: There is an explosion of research in cancer-associated cachexia & this will be of hugely important to patients. #PDAC is the most pro-cachexia malignancy and this profoundly affects patient quality of life. Cancer therapy needs to add high quality life, not just extra time.

1 0 4 203 0

View Details

KenOliveLab @KenOliveLab

2 years ago

@CJHPhD @NCICancerBio Yeah, I think that basically every topic of research in the PDAC field will need to be revisited in the context of RAS inhibition. When it becomes part of the SOC, eventually nearly all PDAC tumors will have seen RAS inhibitor at some point in their treatment history.

0 0 2 50 0

View Details

KenOliveLab @KenOliveLab

2 years ago

@NCICancerBio A8: Physicians are seeing more and more young-onset #PancreaticCancer cases. We need to understand the etiology and go big on prevention and early interception strategies. #PCAMChat24

0 0 4 108 0

View Details

KenOliveLab @KenOliveLab

2 years ago

@NCICancerBio That is, specifically on spatial data.

0 0 1 30 0

View Details

KenOliveLab @KenOliveLab

2 years ago

@NCICancerBio A7: A major key here will be in the analysis tools used to explore these (absolutely massive) datasets. We are again in a situation where our ability to generate data is outstripping the tools we have to analyze. I'm excited by the potential for leveraging powerful sysbio tools!

1 0 1 55 0

View Details

KenOliveLab @KenOliveLab

2 years ago

@DelgiornoKathy @NCICancerBio @AshleyKiemen Yes. These tools have incredible potential power and need to be used more widely!

0 0 0 21 0

View Details

KenOliveLab @KenOliveLab

2 years ago

@NCICancerBio I was pretty sure that everyone else could type "spatial transcriptomics!" faster than I could. ;-)

0 0 2 62 0

View Details

KenOliveLab @KenOliveLab

2 years ago

@NCICancerBio Another big question will be the difference between mutation-selective RAS inhibitors and pan-RAS inhibitors. There are potential advantages and disadvantages to each strategy. Maybe the answer is both?

0 0 4 55 0

View Details

KenOliveLab @KenOliveLab

2 years ago

@NCICancerBio As @cemccarthy02 is highlighting, the next big question will be what to combine with RAS inhibitors. It is on the preclinical PDAC research community to figure this out. Immunotherapy, other targeted therapies, metabolic therapies, etc.

0 0 6 43 0

View Details

KenOliveLab @KenOliveLab

2 years ago

@NCICancerBio A6: Definitely need to highlight RAS inhibition as the dawn of a new era for the treatment of #PDAC patients. The remarkable progress of pan-RAS inhibitors in the clinic (now in Phase 3!) has be super excited and closely linked to preclinical development efforts. #PCAMChat24

0 0 4 124 0

View Details

KenOliveLab @KenOliveLab

2 years ago

Sad to miss the first #PCAMChat24. Briefly, this is Ken Olive from @columbiacancer. I lead a translational research lab dedicated to #PDAC research. Excited to join in for part 2!

0 0 10 706 0

View Details

KenOliveLab @KenOliveLab

2 years ago

@cemccarthy02 @NCICancerBio

0 2 2 21 0

View Details

KenOliveLab @KenOliveLab

2 years ago

Suddenly seeing a huge number of fellow scientists show up on BlueSky. FYI I'm one of them. Come follow me: @kenolivelab.bsky.social

2 0 5 567 0

View Details

Anirban Maitra @Aiims1742

2 years ago

ICYMI, the new issue of @CR_AACR is online and features the print version of the In Focus commentary #PancreaticCancer–Associated Fibroblasts: Where Do We Go from Here? aacrjournals.org/cancerres/arti… By Eileen Carpenter, @DebVendramini @MC_Hasselluhn @MaraShermanLab @Pasca_Lab @ednacukierman @KenOliveLab

0 13 36 5K 13

View Details

KenOliveLab @KenOliveLab

2 years ago

New post on our website with updated information on the clinical development of RAS inhibitors for pancreatic cancer. I'll summarize on twitter sooner, but here's the full version: olivelab.org/ras-inhibitor-…

1 14 43 4K 9

View Details

KenOliveLab @KenOliveLab

2 years ago

@Aiims1742 @PancPathologist @lauradelongwood @deniswirtz These drawings are spectacular. Extraordinary intersection of art and science!

0 0 2 257 0

View Details

Brian Henick @BHenickMD

2 years ago

On behalf of our Phase I program @columbiacancer , proud of @bherzbergmd presenting exciting initial data on IDE397 in MTAP-del tumors at the @EORTC - @theNCI - @AACR conference ir.ideayabio.com/2024-10-25-IDE… We are excited to offer this study to our patients recruit.cumc.columbia.edu/studyinfopage/…

1 6 49 4K 3

View Details

KenOliveLab @KenOliveLab

2 years ago

@AlvaroCurielGa1 @nih It's cool, but is it me or is @nih sending some subtle hints about the relative importance of immune cells vs. fibroblasts here...